Search Results

ACCOAST-PCI Evaluates Pretreatment Strategy With Prasugrel

December 19, 2014—Gilles Montalescot, MD, et al published findings from the ACCOAST-PCI study in the Journal of the American College of Cardiology (JACC; 2014;64:2563–2571).

Prasugrel Assessed in Acute STEMI Patients

February 27, 2009—Daiichi Sankyo Company, Ltd (Tokyo, Japan) and Eli Lilly and Company (Indianapolis, IN), the makers of prasugrel, announced the publication of results from a prespecified analysis of the phase 3 TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) study by Professor Gilles Montalescot, MD, et al in The Lancet (2009;373:723-731).

ATLANTIC-H24 Shows Ambulance-Administered Ticagrelor Reduces Ischemic Events 24 Hours After PCI

September 8, 2015—The European Society of Cardiology (ESC) announced that findings from the ATLANTIC-H24 study showed that P2Y12 antagonist ticagrelor (Brilinta, AstraZeneca) administered in the ambulance reduces ischemic events 24 hours after primary percutaneous coronary intervention (PCI).

Accumetrics Obtains CE Mark for Therapeutic Window Claim on the VerifyNow P2Y12 Test

April 16, 2013–Accumetrics, Inc. (San Diego, CA) announced an expansion in the intended use for the company's CE Mark-approved VerifyNow P2Y12 test.

Stentys' APPOSITION III Data Demonstrates Low Mortality Rates in STEMI Patients

March 9, 2013—Stentys (Paris, France) announced 1-year results of the APPOSITION III clinical trial at the 62nd Annual Sessions of the American College of Cardiology (ACC) being held in San Francisco on March 9–11.

GRACE Registry Shows PCI and CABG to Be Complementary in ULMCAD

September 1, 2009—At the European Society of Cardiology (ESC) Congress in Barcelona, Spain, the GRACE (Global Registry of Acute Coronary Events) registry analysis of a group of high-risk emergency department patients was presented and showed that percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) surgery proved to be "complementary" strategies for patients with unprotected left main coronary artery disease (ULMCAD).